Analytical Dual Agonist

Tirzepatide LY3298176

A first-in-class unimolecular dual GIP and GLP-1 receptor agonist research compound. Linear 39-amino acid architecture (C₂₂₅H₃₄₈N₄₈O₆₈) for high-precision metabolic studies.

Molecular Engineering Data

Molecular FormulaC₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight4813.45 g/mol

CAS Registry2023788-19-2

Sequence39-Amino Acid Peptide

Structure ModificationC20 Fatty Diacid

Assay (HPLC)>99.2% Purity

The “Twincretin” Dual-Agonism Logic

Tirzepatide represents a major shift in incretin research, moving beyond the mono-agonism of traditional compounds. As a unimolecular agonist, it is engineered to concurrently activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual-engagement strategy is studied for its synergistic effects on glucose homeostasis and insulin sensitivity, often yielding data that exceeds the sum of individual receptor activation.

GIP
Receptor Affinity

Potency at the GIP receptor is designed to be comparable to native GIP, modulating white adipose tissue (WAT) and systemic lipid clearance.

GLP-1
Receptor Balance

Affinity for the GLP-1 receptor is calibrated to be ~5x weaker than native GLP-1, a specific “imbalanced” design intended to optimize metabolic outcomes.

Biochemical Architecture

The primary sequence is a 39-amino acid chain based on the native GIP sequence. The critical engineering feature is the attachment of a C20 fatty diacid moiety via a linker at position 20.

Tirzepatide Structure

The C20 moiety facilitates high albumin binding, extending the research half-life to approximately 5 days in in-vivo models.

Research Applications

Beta-Cell Preservation: Studying insulin-producing cell stability.
Lipidomics: Mapping triglyceride and cholesterol fraction shifts.
Neuroprotection: Investigating GIP/GLP-1 cross-talk in the CNS.
Gastric Dynamics: Researching the delay in gastric emptying.
Metabolic Synergy: Analyzing AKT and cAMP signaling pathways.

Laboratory Protocol & Handling

Storage & Stability
Lyophilised powder is stable for extended periods, but reconstituted liquid is highly temperature-dependent.

Long-Term (Powder): -20°C (Up to 24 Months).
Transit Stability: Room temp stable for 7-10 days.
Reconstituted: Must be kept at 2-8°C. Protect from light.

Reconstitution SOP
High solubility in aqueous research media.

Recommended Solvent: Sterile Water or 0.9% NaCl.
Technique: Slow side-wall injection. Do not agitate.
Unit Configurations: Available in 15mg, 20mg, 40mg, and 60mg vials.

Theoretical Framework: Imbalanced Agonism

A primary point of interest for researchers is Tirzepatide’s “imbalanced” affinity profile. By engaging the GIP receptor with high potency while maintaining a lower affinity for the GLP-1 receptor, the compound is hypothesized to minimize the adverse events typically associated with full GLP-1 receptor saturation while maximizing metabolic output through GIP-mediated insulin sensitization. Current research focuses on how this specific ratio affects the AMPK pathway and the modulation of glucagon secretion in post-prandial models.

Strict Laboratory Compliance Notice

WARNING: This compound is a chemical reagent supplied exclusively for in-vitro and in-vivo laboratory research. It is NOT a drug, medication, food, or dietary supplement. Strictly prohibited for human or veterinary administration. By initiating a procurement sequence, the user confirms they are a qualified professional working within a controlled research environment and accept full legal responsibility for the lawful handling of this material.